|
[1] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.
|
|
[2] Global Burden of Disease Liver Cancer Col aboration,AKINYEMIJU T,ABERA S,et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,regional,and national level:Results from the Global Burden of Disease Study2015[J]. JAMA Oncol,2017,3(12):1683-1691.
|
|
[3] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[4] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
|
|
[5] EL-SERAG HB,MARRERO JA,RUDOLPH L,et al. Diagnosis and treatment of hepatocellular carcinoma[J]. Gastroenterology,2008,134(6):1752-1763.
|
|
[6] SEOANE J,de MATTOS-ARRUDA L,LE RHUN E,et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases[J]. Ann Oncol,2019,30(2):211-218.
|
|
[7] MANDEL P,MTAIS P. Les acides nucléiques du plasma sanguin chez l'homme[J]. Cr Acad Sci Paris,1948,142(3-4):241-243.
|
|
[8] WALDRON D. Cancer genomics:A nucleosome footprint reveals the source of cfDNA[J]. Nat Rev Genet,2016,17(3):125.
|
|
[9] MOULIERE F,CHANDRANANDA D,PISKORZ AM,et al. Enhanced detection of circulating tumor DNA by fragment size analysis[J]. Sci Transl Med,2018,10(466):eaat4921.
|
|
[10] DIAZ LA Jr,BARDELLI A. Liquid biopsies:Genotyping circulating tumor DNA[J]. J Clin Oncol,2014,32(6):579-586.
|
|
[11] SNYDER MW,KIRCHER M,HILL AJ,et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin[J]. Cell,2016,164(1-2):57-68.
|
|
[12] TUG S,HELMIG S,DEICHMANN ER,et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage[J].Exerc Immunol Rev,2015,21:164-173.
|
|
[13] LEHMANN-WERMAN R,NEIMAN D,ZEMMOUR H,et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA[J]. Proc Natl Acad Sci U S A,2016,113(13):e1826-e1834.
|
|
[14] BREITBACH S,TUG S,SIMON P. Circulating cell-free DNA:An up-coming molecular marker in exercise physiology[J].Sports Med,2012,42(7):565-586.
|
|
[15] CROWLEY E,di NICOLANTONIO F,LOUPAKIS F,et al. Liquid biopsy:Monitoring cancer-genetics in the blood[J]. Nat Rev Clin Oncol,2013,10(8):472-484.
|
|
[16] THIERRY AR,EL MESSAOUDI S,GAHAN PB,et al. Origins,structures,and functions of circulating DNA in oncology[J].Cancer Metastasis Rev,2016,35(3):347-376.
|
|
[17] TAMKOVICH SN,CHEREPANOVA AV,KOLESNIKOVA EV,et al. Circulating DNA and DNase activity in human blood[J].Ann N Y Acad Sci,2006,1075:191-196.
|
|
[18] HOLDENRIEDER S,STIEBER P,BODENMLLER H,et al.Nucleosomes in serum of patients with benign and malignant diseases[J]. Int J Cancer,2001,95(2):114-120.
|
|
[19] PETERS DL,PRETORIUS PJ. Origin,translocation and destination of extracellular occurring DNA-a new paradigm in genetic behaviour[J]. Clin Chim Acta,2011,412(11-12):806-811.
|
|
[20] HOLMGREN L,BERGSMEDH A,SPETZ AL. Horizontal transfer of DNA by the uptake of apoptotic bodies[J]. Vox Sang,2002,83(Suppl 1):305-306.
|
|
[21] EMMANOUILIDI A,PALADIN D,GREENING DW,et al. Oncogenic and non-malignant pancreatic exosome cargo reveal distinct expression of oncogenic and prognostic factors involved in tumor invasion and metastasis[J]. Proteomics,2019,19(8):e1800158.
|
|
[22] SANTOS C,AZUARA D,VIITEZ JM,et al. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI:The ULTRA trial[J]. Ann Oncol,2019,30(5):796-803.
|
|
[23] RAZAVI P,LI BT,BROWN DN,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants[J]. Nat Med,2019,25(12):1928-1937.
|
|
[24] CHAUDHURI AA,BINKLEY MS,OSMUNDSON EC,et al. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA[J]. Semin Radiat Oncol,2015,25(4):305-312.
|
|
[25] CAO Z,WANG J,QIN N,et al. Clinical value of droplet digital PCR and super-ARMS detection of epidermal growth factor receptor gene mutation in plasma circulating tumor DNA of patients with advanced lung adenocarcinoma[J]. Chin J Lung Cancer,2020,23(2):84-90.(in Chinese)曹喆，王静，秦娜，等．微滴数字PCR和Super-ARMS检测晚期肺腺癌患者血浆循环肿瘤DNA表皮生长因子受体基因突变的临床价值研究[J]．中国肺癌杂志，2020,23(2):84-90.
|
|
[26] BUSSER B,LUPO J,SANCEY L,et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients:Landscape of available technologies and clinical applications[J]. Biomed Res Int,2017,2017:5986129.
|
|
[27] LI YQ,SONG SS,JIANG SH,et al. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C[J]. Ann Oncol,2017,28(10):2622-2624.
|
|
[28] GARLAN F,LAURENT-PUIG P,SEFRIOUI D,et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients(PLACOL Study)[J]. Clin Cancer Res,2017,23(18):5416-5425.
|
|
[29] THIERRY AR,MOULIERE F,el MESSAOUDI S,et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA[J]. Nat Med,2014,20(4):430-435.
|
|
[30] FENG WN,GU WQ,ZHAO N,et al. Comparison of the superARMS and droplet digital PCR for detecting EGFR mutation in ctDNA from NSCLC patients[J]. Transl Oncol,2018,11(2):542-545.
|
|
[31] LI C,HE Q,LIANG H,et al. Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer:A Meta-analysis[J]. Front Oncol,2020,10:290.
|
|
[32] MARKOU A,TZANIKOU E,LADAS I,et al. Nuclease-assisted minor allele enrichment using overlapping probes-assisted amplification-refractory mutation system:An approach for the improvement of amplification-refractory mutation systempolymerase chain reaction specificity in liquid biopsies[J]. Anal Chem,2019,91(20):13105-13111.
|
|
[33] CAI Z,CHEN G,ZENG Y,et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in longterm follow-up patients with hepatocellular carcinoma[J].Clin Cancer Res,2019,25(17):5284-5294.
|
|
[34] JIANG P,CHAN CW,CHAN KC,et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients[J]. Proc Natl Acad Sci U S A,2015,112(11):e1317-e1325.
|
|
[35] KISIEL JB,DUKEK BA,V S R KANIPAKAM R,et al. Hepatocellular carcinoma detection by plasma methylated DNA:Discovery,phase I pilot,and phase II clinical validation[J].Hepatology,2019,69(3):1180-1192.
|
|
[36] COHEN JD,LI L,WANG Y,et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science,2018,359(6378):926-930.
|
|
[37] XU RH,WEI W,KRAWCZYK M,et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater,2017,16(11):1155-1161.
|
|
[38] LI F,QIAO CY,GAO S,et al. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy[J]. Free Radic Res,2018,52(4):455-464.
|
|
[39] MARCHIO A,AMOUGOU ATSAMA M,BRA,et al. Droplet digital PCR detects high rate of TP53 R249S mutants in cellfree DNA of middle African patients with hepatocellular carcinoma[J]. Clin Exp Med,2018,18(3):421-431.
|
|
[40] NG C,di COSTANZO GG,TOSTI N,et al. Genetic profiling using plasma-derived cell-free DNA in therapy-nave hepatocellular carcinoma patients:A pilot study[J]. Ann Oncol,2018,29(5):1286-1291.
|
|
[41] RUMIATO E,BOLDRIN E,MALACRIDA S,et al. Detection of genetic alterations in cfDNA as a possible strategy to monitor the neoplastic progression of Barrett’s esophagus[J]. Transl Res,2017,190:16-24.
|
|
[42] IKEDA S,LIM JS,KURZROCK R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma:Implications for targeted therapeutics[J]. Mol Cancer Ther,2018,17(5):1114-1122.
|
|
[43] CAI ZX,CHEN G,ZENG YY,et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer,2017,141(5):977-985.
|
|
[44] IKEDA S,TSIGELNY IF,SKJEVIKA,et al. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma[J]. Oncologist,2018,23(5):586-593.
|
DownLoad: